Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -247.39% is 77% above its 5-year average of -1078.71%, near the high end of its 5-year range (-3219.34%–-39.33%).
154.12% below its 12-month average of -97.35%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -61.16%.
RETURN ON ASSETS (ROA)
-247.39%
RETURN ON ASSETS (ROA) AVG TTM
-97.35%
RETURN ON ASSETS (ROA) AVG 3Y
-1378.80%
RETURN ON ASSETS (ROA) AVG 5Y
-1078.71%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-154.12%
CURRENT VS 3Y AVG
+82.06%
CURRENT VS 5Y AVG
+77.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-667.34%
vs the sector median at left
Jupiter Neurosciences, Inc.
Market Cap
$1.36M
Return on Assets (ROA)
-247.39%
TTM Avg
-97.35%
3Y Avg
-1378.80%
5Y Avg
-1078.71%
Market Cap
$1.33M
Return on Assets (ROA)
-72.52%
TTM Avg
-80.61%
3Y Avg
-249.55%
5Y Avg
-240.26%
Market Cap
$1.33M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
Market Cap
$1.32M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
Market Cap
$1.42M
Return on Assets (ROA)
-20.46%
TTM Avg
-67.47%
3Y Avg
-117.99%
5Y Avg
-101.96%
Market Cap
$1.45M
Return on Assets (ROA)
-23.39%
TTM Avg
-29.27%
3Y Avg
-34.02%
5Y Avg
-43.63%
Market Cap
$1.48M
Return on Assets (ROA)
-36.88%
TTM Avg
-64.67%
3Y Avg
-76.84%
5Y Avg
-289.12%
Market Cap
$1.48M
Return on Assets (ROA)
-111.51%
TTM Avg
-71.56%
3Y Avg
-64.13%
5Y Avg
-49.86%
Market Cap
$1.51M
Return on Assets (ROA)
-148.13%
TTM Avg
-399.46%
3Y Avg
-266.31%
5Y Avg
-266.31%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.36M | -247.39% | -97.35% | -1378.80% | -1078.71% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -72.52% | -80.61% | -249.55% | -240.26% |
| Genprex, Inc. (GNPX)vs › | $1.33M | -96.27% | -335.81% | -263.87% | -193.48% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.32M | -196.18% | -334.48% | -197.38% | -169.68% |
| INVO Fertility, Inc. (IVF)vs › | $1.42M | -20.46% | -67.47% | -117.99% | -101.96% |
| NEXGEL, Inc. (NXGL)vs › | $1.45M | -23.39% | -29.27% | -34.02% | -43.63% |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | -36.88% | -64.67% | -76.84% | -289.12% |
| Curis, Inc. (CRIS)vs › | $1.48M | -111.51% | -71.56% | -64.13% | -49.86% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.51M | -148.13% | -399.46% | -266.31% | -266.31% |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | -64.99% | -31.34% | -98.36% | -79.15% |
ROA
-247.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -155.37% |
| 2024-12-31 | -39.33% |
| 2023-12-31 | -3219.34% |
| 2022-12-31 | -2101.17% |
| 2021-12-31 | -656.21% |
| 2020-12-31 | -300.86% |
| 2019-12-31 | -49323.60% |
